The best known members of genus Mycobacterium belong to M. tuberculosis complex. Other mycobacteria are known as nontuberculous mycobacteria (NTM). NTM less commonly cause a disease (mycobacteriosis), more often colonising respiratory tract. The presence of NTM is more common in immunocompromised patients and in those with a previous lung disease. The decrease in the incidence of tuberculosis is followed by increased incidence of NTM. Since tuberculosis has been declining in Croatia over the last 50 years, increasing incidence of NTM is expected. Growing incidence of chronic obstructive pulmonary disease (COPB) is contributing to this increase. NTM are ubiquitous and inhaling of aerosol particles constitutes the dominant route of infection. They are not transmitted via interhuman contact. In addition to pulmonary and skin infections, disseminated infections are also described. The treatment of mycobacteriosis is difficult and long. Besides using antituberculotic drugs such as rifampin and ethambutol, the therapies use fluoroquinolones; the introduction of macrolides has significantly improved the outcome of treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A genome-wide association study identified PRKCB as a causal gene and therapeutic target for Mycobacterium avium complex disease.
Cell Rep Med
January 2025
Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address:
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic progressive lung disease that is increasing in incidence. Host genetic factors are associated with NTM-PD susceptibility. However, the heritability of NTM-PD is not well understood.
View Article and Find Full Text PDFEpidemiology and clinical outcomes in skin and soft tissue nontuberculous mycobacteria infections: A retrospective study.
J Infect Public Health
January 2025
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:
Article Synopsis
- Nontuberculous mycobacteria (NTM) are increasingly recognized as pathogens causing skin and soft tissue infections (SSTIs), facing diagnostic and treatment obstacles due to the absence of standardized guidelines.
- A study analyzed data from 142 patients diagnosed with NTM SSTIs over a nine-year period, revealing the most common species were M. marinum, MAC, and MABC, with a significant annual increase in cases and a notable prevalence of immunocompromised patients, particularly in the MAC group.
- Misdiagnosis was common, with most cases initially mistaken for skin tuberculosis or bacterial infections; amikacin was identified as the most effective antibiotic, while resistance to other drugs like cefoxitin was frequent among certain NTM
Disseminated infection in an immunocompromised adult: An uncommon etiology of skin infection.
IDCases
December 2024
Department of Medicine, Mary Washington Healthcare, Fredericksburg, VA, USA.
is a rapidly growing nontuberculous mycobacterium (NTM) that is ubiquitous in the environment and is associated with skin and soft tissue infections (1). Because is an opportunistic infection, it can present as skin abscess, cellulitis, osteomyelitis, pulmonary infection or disseminated infections, particularly in individuals with compromised immune systems or underlying lung conditions such as cystic fibrosis or bronchiectasis. is one of the most pathogenic rapidly growing mycobacteria (RGM).
View Article and Find Full Text PDFBackground: Due to its increasing prevalence and suboptimal treatment, non-tuberculous mycobacterial (NTM) infection is an emerging problem in patients with cystic fibrosis (CF). Detailed description of regional NTM prevalence and distribution, and identification of predictors of NTM acquisition in CF are essential to optimise treatment and surveillance guidelines.
Methods: A retrospective, multi-center analysis was conducted between the years 2020 and 2022 on data from 232 adult patients registered in the Hungarian CF Registry in 2022.
Clinically significant hemoptysis and all-cause mortality in patients with nontuberculous mycobacterial pulmonary disease.
Respir Med
January 2025
Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Department of Microbiology, Harvard Medical School, Boston, United States. Electronic address:
Background: Hemoptysis is one of the major symptoms in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). However, its prevalence, incidence, and impact on long-term prognosis remain uncertain. We evaluated the incidence of clinically significant hemoptysis, and determined its association with mortality in patients with NTM-PD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!